Key Highlights

Consolidated revenues at Rs. 18.4 billion ($382 million) in Q2 FY10 as against Rs. 16.2 billion ($336 million) in Q2 FY09, representing a growth of 14%. The growth is largely driven by Global Generics.

Consolidated revenues for H1 FY10 at Rs. 36.6 billion represent a YoY growth of 17%.

Sequentially, as compared to Q1 FY10, the revenues excluding sumatriptan have grown by 11%.

Operating income at Rs. 2.6 billion ($53 million) in Q2 FY10 as against Rs. 1.8 billion ($37 million) in Q2 FY09.

EBITDA at Rs. 3.8 billion ($79 million) in Q2 FY10 as against Rs. 2.5 billion ($52 million) in Q2 FY09, representing a growth of 51%.

EBITDA for H1 FY10 at Rs. 8.2 billion represents a YoY growth of 70%.

Revenues from Global Generics business at Rs. 12.7 billion ($264 million) in Q2 FY10 as against Rs. 11.1 billion ($231 million) in Q2 FY09. YoY growth of 14% driven by key markets of North America, Russia and India.

Revenues for H1 FY10 at Rs. 25.7 billion represent a YoY growth of 20%.

Revenues from Pharmaceutical Services & Active Ingredients (PSAI) increase by 11% to Rs. 5.4 billion ($112 million) in Q2 FY10 as against Rs. 4.8 billion ($100 million) in Q2 FY09.

Revenues for H1 FY10 at Rs. 10.2 billion represent a YoY growth of 9%.

During the quarter, the company launched 39 new generic products, filed 24 new product registrations and filed 5 DMFs globally.

                                                                                                                                                 
 All figures in millions, except EPS                                 All dollar figures based on convenience translation rate of 1USD = Rs 48.09 
                                                                                                                                                 
 Dr.